Study Question:
What is the global, regional and national burden of polycystic ovary syndrome (PCOS), by age and socio-demographic index (SDI), over the period 1990-2019?
Summary Answer:
In 2019, the global age-standardized point prevalence, incidence and years lived with disability (YLD) of PCOS were 30.4, 29.5 and 29.9 per 100 000 population, respectively.
What Is Known Already:
Data from the Global Burden of Disease (GBD) study 2017 showed that the global age-standardized PCOS incidence rate increased 1.45% over the period 1990-2017.
Study Design, Size, Duration:
A systematic analysis of the PCOS prevalence, incidence and YLDs across 204 countries and territories was performed.
Participants/materials, Setting, Methods:
Data on the point prevalence, annual incidence and YLDs due to PCOS were retrieved from the GBD study 2019 for 204 countries and territories from 1990 to 2019. The counts and age-standardized rates (per 100 000) are presented, along with their corresponding 95% uncertainty intervals (UIs).
Main Results And The Role Of Chance:
In 2019, the global age-standardized point prevalence and annual incidence rates for PCOS were 1677.8 (95% UI: 1166.0 to 2192.4) and 59.8 (95% UI: 41.7 to 78.9) per 100 000, which represents a 30.4% and 29.5% increase since 1990, respectively. Moreover, the global age-standardized YLD rate in 2019 was 14.7 (6.3-29.5), an increase of 29.9% since 1990. In 2019, Italy (7897.0), Japan (6298.7) and New Zealand (5419.1) had the highest estimated age-standardized point prevalences of PCOS. Globally, the number of prevalent cases and the point prevalence of PCOS peaked in the 25-29 years and 40-44 years age groups, respectively. Positive associations were found between the burden of PCOS and the SDI at the regional and national levels.
Limitations, Reasons For Caution:
Variations in how PCOS was defined is a major limitation that prevents valid comparisons between different regions.
Wider Implications Of The Findings:
Globally, the burden of PCOS has increased at an alarming rate, making it a major public health concern. Increasing public awareness about this common condition, improving management options and increasing support to reduce factors which lead to further complications, need to be public health priorities.
Study Funding/competing Interest(s):
The Bill and Melinda Gates Foundation, who were not involved in any way in the preparation of this manuscript, funded the GBD study. The Shahid Beheshti University of Medical Sciences, Tehran, Iran (Grant No. 28709) also supported the present report. The authors declare no competing interests.
Trial Registration Number:
N/A.
Citing Articles
Ovarian dysfunction and polycystic ovary syndrome in the U.S. military active component, 2014-2023.
Douthitt W, Murray J, Stahlman S
MSMR. 2025; 32(1):11-17.
PMID: 39965137
PMC: 11844305.
Transgenerational inheritance of diabetes susceptibility in male offspring with maternal androgen exposure.
Zhang Y, Hu S, Han S, Liu C, Liang X, Li Y
Cell Discov. 2025; 11(1):14.
PMID: 39934105
PMC: 11814079.
DOI: 10.1038/s41421-025-00769-1.
The Global Burden of Polycystic Ovary Syndrome in Women of Reproductive Age: Findings from the GBD 2019 Study.
Jiang B
Int J Womens Health. 2025; 17:153-165.
PMID: 39882398
PMC: 11776423.
DOI: 10.2147/IJWH.S490836.
Evaluation of ovarian stiffness and its biological mechanism using shear wave elastography in polycystic ovary syndrome.
He Y, Deng S, Wang Y, Wang X, Huang Q, Cheng J
Sci Rep. 2025; 15(1):585.
PMID: 39747947
PMC: 11695736.
DOI: 10.1038/s41598-024-84338-8.
Unveiling the molecular landscape of PCOS: identifying hub genes and causal relationships through bioinformatics and Mendelian randomization.
He Y, Wang Y, Wang X, Deng S, Wang D, Huang Q
Front Endocrinol (Lausanne). 2024; 15:1431200.
PMID: 39735641
PMC: 11671271.
DOI: 10.3389/fendo.2024.1431200.
Microbial harmony in female reproductive health: exploring the impact of intestinal flora on ovarian function and disease pathogenesis.
Luo X, Guo Y, Xu L
Am J Transl Res. 2024; 16(11):6274-6288.
PMID: 39678593
PMC: 11645629.
DOI: 10.62347/GDNO7274.
The effect of mindfulness-based art therapy (MBAT) on the body image of women with polycystic ovary syndrome (PCOS): a randomized controlled trial.
Bafghi Z, Ahmadi A, Mirzaee F, Ghazanfarpour M
BMC Psychiatry. 2024; 24(1):611.
PMID: 39261845
PMC: 11391753.
DOI: 10.1186/s12888-024-06057-8.
Constructing a predictive model for live birth following fresh embryo transfer in antagonist protocol for polycystic ovary syndrome.
Zhu S, Chen X, Li R, Jiang W, Zheng B, Sun Y
J Assist Reprod Genet. 2024; 41(10):2709-2719.
PMID: 39168929
PMC: 11534932.
DOI: 10.1007/s10815-024-03232-4.
Genetic insights of blood lipid metabolites on polycystic ovary syndrome risk: a bidirectional two-sample Mendelian randomization study.
Wang X, Han H, Shi X, Nie X, Zhu R, Jin J
Front Endocrinol (Lausanne). 2024; 15:1391826.
PMID: 39045272
PMC: 11263216.
DOI: 10.3389/fendo.2024.1391826.
Global burden and epidemiological prediction of polycystic ovary syndrome from 1990 to 2019: A systematic analysis from the Global Burden of Disease Study 2019.
Zhang J, Zhu Y, Wang J, Hu H, Jin Y, Mao X
PLoS One. 2024; 19(7):e0306991.
PMID: 39024211
PMC: 11257291.
DOI: 10.1371/journal.pone.0306991.
The gut microbial composition in polycystic ovary syndrome with hyperandrogenemia and its association with steroid hormones.
Li M, Chang Q, Luo Y, Pan J, Hu Y, Liu B
Front Cell Dev Biol. 2024; 12:1384233.
PMID: 38872933
PMC: 11169812.
DOI: 10.3389/fcell.2024.1384233.
Developing a Novel Web-Based Self-Management Support Intervention for Polycystic Ovary Syndrome: Mixed Methods Study With Patients and Health Care Professionals.
Percy C, Turner A, Orr C
JMIR Form Res. 2024; 8:e52427.
PMID: 38451567
PMC: 10958350.
DOI: 10.2196/52427.
Arachidonic acid inhibit granulosa cell function by affecting metabolic function of liver in brown adipose transplantation rats.
Yan Y, Di F, Zhang R, Song L, Zhang R, Qiu J
J Ovarian Res. 2024; 17(1):43.
PMID: 38374173
PMC: 10875878.
DOI: 10.1186/s13048-024-01374-8.
A systematic review and future research agenda on detection of polycystic ovary syndrome (PCOS) with computer-aided techniques.
Suha S, Islam M
Heliyon. 2023; 9(10):e20524.
PMID: 37867807
PMC: 10589778.
DOI: 10.1016/j.heliyon.2023.e20524.
Polycystic ovary syndrome: pathophysiology and therapeutic opportunities.
Dong J, Aled Rees D
BMJ Med. 2023; 2(1):e000548.
PMID: 37859784
PMC: 10583117.
DOI: 10.1136/bmjmed-2023-000548.
The impact of sleeve gastrectomy on polycystic ovarian syndrome: a single-center 1-year cohort study.
Malekpour Alamdari N, Sadegh G, Farsi Y, Besharat S, Hajimirzaie S, Abbasi M
Ir J Med Sci. 2023; 193(2):721-724.
PMID: 37574528
DOI: 10.1007/s11845-023-03488-2.
Direct economic burden of mental health disorders associated with polycystic ovary syndrome: Systematic review and meta-analysis.
Yadav S, Delau O, Bonner A, Markovic D, Patterson W, Ottey S
Elife. 2023; 12.
PMID: 37534878
PMC: 10471160.
DOI: 10.7554/eLife.85338.
Immunological and Metabolic Causes of Infertility in Polycystic Ovary Syndrome.
Kicinska A, Maksym R, Zabielska-Kaczorowska M, Stachowska A, Babinska A
Biomedicines. 2023; 11(6).
PMID: 37371662
PMC: 10295970.
DOI: 10.3390/biomedicines11061567.
Polycystic Ovary Syndrome: Challenges and Possible Solutions.
Che Y, Yu J, Li Y, Zhu Y, Tao T
J Clin Med. 2023; 12(4).
PMID: 36836035
PMC: 9967025.
DOI: 10.3390/jcm12041500.
Successful Implementation of Menstrual Cycle Biomarkers in the Treatment of Infertility in Polycystic Ovary Syndrome-Case Report.
Kicinska A, Stachowska A, Kajdy A, Wierzba T, Maksym R
Healthcare (Basel). 2023; 11(4).
PMID: 36833150
PMC: 9956032.
DOI: 10.3390/healthcare11040616.